304 related articles for article (PubMed ID: 12871164)
1. Advances in angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).
Swamy KM; Lin MJ; Sun CM
Mini Rev Med Chem; 2003 Sep; 3(6):621-31. PubMed ID: 12871164
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin receptor blockers: evidence for preserving target organs.
Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together?
Verdecchia P; Angeli F; Mazzotta G; Ambrosio G; Reboldi G
Curr Vasc Pharmacol; 2010 Nov; 8(6):742-6. PubMed ID: 20626343
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor blockers for the treatment of hypertension.
See S
Expert Opin Pharmacother; 2001 Nov; 2(11):1795-804. PubMed ID: 11825317
[TBL] [Abstract][Full Text] [Related]
5. Drug Treatment of Hypertension: Focus on Vascular Health.
Cameron AC; Lang NN; Touyz RM
Drugs; 2016 Oct; 76(16):1529-1550. PubMed ID: 27667708
[TBL] [Abstract][Full Text] [Related]
6. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
7. The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines.
Alcocer LA; Bryce A; De Padua Brasil D; Lara J; Cortes JM; Quesada D; Rodriguez P
Am J Cardiovasc Drugs; 2023 Nov; 23(6):663-682. PubMed ID: 37668854
[TBL] [Abstract][Full Text] [Related]
8. Should ACE inhibitors and ARBs be used in combination in children?
Stotter BR; Ferguson MA
Pediatr Nephrol; 2019 Sep; 34(9):1521-1532. PubMed ID: 30112656
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
[TBL] [Abstract][Full Text] [Related]
10. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
11. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
12. Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Singh RK; Barker S
Curr Opin Investig Drugs; 2005 Mar; 6(3):269-74. PubMed ID: 15816503
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
Rodgers JE; Patterson JH
Am J Health Syst Pharm; 2001 Apr; 58(8):671-83. PubMed ID: 11329759
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
Ohtsubo T; Shibata R; Kai H; Okamoto R; Kumagai E; Kawano H; Fujiwara A; Kitazono T; Murohara T; Arima H
Hypertens Res; 2019 May; 42(5):641-649. PubMed ID: 30948834
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-II receptor antagonists: their place in therapy.
Kirk JK
Am Fam Physician; 1999 Jun; 59(11):3140-8. PubMed ID: 10392595
[TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
[TBL] [Abstract][Full Text] [Related]
17. Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension.
Ahad A; Al-Mohizea AM; Al-Jenoobi FI; Aqil M
Drug Deliv; 2016; 23(2):579-90. PubMed ID: 25065883
[TBL] [Abstract][Full Text] [Related]
18. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
Verdecchia P; Gentile G; Angeli F; Reboldi G
Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
[TBL] [Abstract][Full Text] [Related]
19. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
20. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.
Dézsi CA
Am J Cardiovasc Drugs; 2014 Jun; 14(3):167-73. PubMed ID: 24385234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
